Abstract
Background: Among people living with HIV (PLWH), the prevalence of non-HIV related co-morbidities is increasing. Aim of the present study is to describe co-morbidity and multi-morbidity, their clustering mode and the potential disease-disease interactions in a cohort of Italian HIV patients. Methods: Cross-sectional analysis conducted by the Coordinamento Italiano per lo Studio di Allergia e Infezioni da HIV (CISAI) on adult subjects attending HIV-outpatient facilities. Non-HIV co-morbidities included: cardiovascular disease, diabetes mellitus, hypertension, oncologic diseases, osteoporosis, probable case of chronic obstructive pulmonary disease (COPD), hepatitis C virus (HCV) infection, psychiatric illness, kidney disease. Multi-morbidity was defined as the presence of two or more co-morbidities. Results: One thousand and eighty-seven patients were enrolled in the study (mean age 47.9 ± 10.8). One hundred-ninety patients (17.5%) had no co-morbidity, whereas 285 (26.2%) had one condition and 612 (56.3%) were multi-morbid. The most recurrent associations were: 1) dyslipidemia + hypertension (237, 21.8%); 2) dyslipidemia + COPD (188, 17.3%); 3) COPD + HCV-Ab+ (141, 12.9%). Multi-morbidity was associated with older age, higher body mass index, current and former smoking, CDC stage C and longer ART duration. Conclusions: More than 50% of PLHW were multi-morbid and about 30% had three or more concurrent comorbidities. The identification of common patterns of comorbidities address the combined risks of multiple drug and disease-disease interactions.
| Original language | English |
|---|---|
| Article number | 555 |
| Journal | BMC Infectious Diseases |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jun 25 2019 |
Fingerprint
Keywords
- Clusterization
- Co-morbidity
- Disease-disease interactions
- HIV
- Multi-morbidity
ASJC Scopus subject areas
- Infectious Diseases
Cite this
Clusterization of co-morbidities and multi-morbidities among persons living with HIV : A cross-sectional study. / Maggi, Paolo; Santoro, Carmen R.; Nofri, Marco; Ricci, Elena; De Gennaro, Nicolò; Bellacosa, Chiara; Schiaroli, Elisabetta; Orofino, Giancarlo; Menzaghi, Barbara; Di Biagio, Antonio; Squillace, Nicola; Francisci, Daniela; Vichi, Francesca; Molteni, Chiara; Bonfanti, Paolo; Gaeta, Giovanni Battista; De Socio, Giuseppe Vittorio.
In: BMC Infectious Diseases, Vol. 19, No. 1, 555, 25.06.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clusterization of co-morbidities and multi-morbidities among persons living with HIV
T2 - A cross-sectional study
AU - Maggi, Paolo
AU - Santoro, Carmen R.
AU - Nofri, Marco
AU - Ricci, Elena
AU - De Gennaro, Nicolò
AU - Bellacosa, Chiara
AU - Schiaroli, Elisabetta
AU - Orofino, Giancarlo
AU - Menzaghi, Barbara
AU - Di Biagio, Antonio
AU - Squillace, Nicola
AU - Francisci, Daniela
AU - Vichi, Francesca
AU - Molteni, Chiara
AU - Bonfanti, Paolo
AU - Gaeta, Giovanni Battista
AU - De Socio, Giuseppe Vittorio
PY - 2019/6/25
Y1 - 2019/6/25
N2 - Background: Among people living with HIV (PLWH), the prevalence of non-HIV related co-morbidities is increasing. Aim of the present study is to describe co-morbidity and multi-morbidity, their clustering mode and the potential disease-disease interactions in a cohort of Italian HIV patients. Methods: Cross-sectional analysis conducted by the Coordinamento Italiano per lo Studio di Allergia e Infezioni da HIV (CISAI) on adult subjects attending HIV-outpatient facilities. Non-HIV co-morbidities included: cardiovascular disease, diabetes mellitus, hypertension, oncologic diseases, osteoporosis, probable case of chronic obstructive pulmonary disease (COPD), hepatitis C virus (HCV) infection, psychiatric illness, kidney disease. Multi-morbidity was defined as the presence of two or more co-morbidities. Results: One thousand and eighty-seven patients were enrolled in the study (mean age 47.9 ± 10.8). One hundred-ninety patients (17.5%) had no co-morbidity, whereas 285 (26.2%) had one condition and 612 (56.3%) were multi-morbid. The most recurrent associations were: 1) dyslipidemia + hypertension (237, 21.8%); 2) dyslipidemia + COPD (188, 17.3%); 3) COPD + HCV-Ab+ (141, 12.9%). Multi-morbidity was associated with older age, higher body mass index, current and former smoking, CDC stage C and longer ART duration. Conclusions: More than 50% of PLHW were multi-morbid and about 30% had three or more concurrent comorbidities. The identification of common patterns of comorbidities address the combined risks of multiple drug and disease-disease interactions.
AB - Background: Among people living with HIV (PLWH), the prevalence of non-HIV related co-morbidities is increasing. Aim of the present study is to describe co-morbidity and multi-morbidity, their clustering mode and the potential disease-disease interactions in a cohort of Italian HIV patients. Methods: Cross-sectional analysis conducted by the Coordinamento Italiano per lo Studio di Allergia e Infezioni da HIV (CISAI) on adult subjects attending HIV-outpatient facilities. Non-HIV co-morbidities included: cardiovascular disease, diabetes mellitus, hypertension, oncologic diseases, osteoporosis, probable case of chronic obstructive pulmonary disease (COPD), hepatitis C virus (HCV) infection, psychiatric illness, kidney disease. Multi-morbidity was defined as the presence of two or more co-morbidities. Results: One thousand and eighty-seven patients were enrolled in the study (mean age 47.9 ± 10.8). One hundred-ninety patients (17.5%) had no co-morbidity, whereas 285 (26.2%) had one condition and 612 (56.3%) were multi-morbid. The most recurrent associations were: 1) dyslipidemia + hypertension (237, 21.8%); 2) dyslipidemia + COPD (188, 17.3%); 3) COPD + HCV-Ab+ (141, 12.9%). Multi-morbidity was associated with older age, higher body mass index, current and former smoking, CDC stage C and longer ART duration. Conclusions: More than 50% of PLHW were multi-morbid and about 30% had three or more concurrent comorbidities. The identification of common patterns of comorbidities address the combined risks of multiple drug and disease-disease interactions.
KW - Clusterization
KW - Co-morbidity
KW - Disease-disease interactions
KW - HIV
KW - Multi-morbidity
UR - http://www.scopus.com/inward/record.url?scp=85068175728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068175728&partnerID=8YFLogxK
U2 - 10.1186/s12879-019-4184-z
DO - 10.1186/s12879-019-4184-z
M3 - Article
AN - SCOPUS:85068175728
VL - 19
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
SN - 1471-2334
IS - 1
M1 - 555
ER -